

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 12

Confirmation Number

7706

Application Number

10/813,965

Filing Date

March 31, 2004

First Named Inventor

Robert Falotico

Group Art Unit

1628

Examiner Name

Jennifer M. Kim

Attorney Docket Number

CRD5073USNP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code* (if known)			
	09/948,987			See U.S. Patent 6,764,507		
	3,576,886			Neuwirth	04-27-1971	
	3,862,332			Barnhart, et al.	01-21-1975	
	3,929,992			Sehgal, et al.	12-30-1975	
	3,959,078			Guire	05-25-1976	
	4,350,160			Kolesov, et al.	09-21-1982	
	4,366,819			Kaster	01-04-1983	
	4,368,736			Kaster	01-18-1983	
	4,624,257			Berggren, et al.	11-25-1986	
	4,722,906			Guire	02-02-1988	
	4,733,665			Palmaz	03-29-1988	
	4,739,762			Palmaz	04-26-1988	
	4,776,337			Palmaz	10-11-1988	
	4,814,470			Colin, et al.	02-21-1989	
	4,857,653			Colin, et al.	08-15-1989	
	4,917,090			Berggren, et al.	04-17-1990	

Examiner Signature /Jennifer Kim/

Date Considered 07/22/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 12

Confirmation Number

7706

Application Number

10/813,965

Filing Date

March 31, 2004

First Named Inventor

Robert Falotico

Group Art Unit

1628

Examiner Name

Jennifer M. Kim

Attorney Docket Number

CRD5073USNP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
	4,917,091			Berggren, et al.	04-17-1990	
	4,942,184			Haugwitz, et al.	07-17-1990	
	4,984,060			Ohmi, et al.	01-08-1991	
	5,059,699			Kingston, et al.	10-22-1991	
	5,200,534			Rao	04-06-1993	
	5,202,448	A		Carver, et al.	04-13-1993	
	5,229,172	A		Cahalan, et al.	07-20-1993	
	5,229,529	A		Veno, et al.	07-20-1993	
	5,234,447	A		Kaster, et al.	08-10-1993	
	5,248,796	A		Chen, et al.	09-28-1993	
	5,254,580	A		Chen, et al.	10-19-1993	
	5,272,171	A		Ueda, et al.	12-21-1993	
	5,274,137	A		Nicolaou, et al.	12-28-1993	
	5,278,324	A		Kingston	01-11-1994	
	5,279,949	A		Muraleedharan	01-18-1994	
	5,283,253	A		Holton, et al.	02-01-1994	
	5,294,637	A		Chen, et al.	03-15-1994	
	5,294,997	A		Ogura, et al.	03-15-1994	
	5,300,638	A		Farina, et al.	04-05-1994	
	5,308,641	A		Cahalan, et al.	05-03-1994	

Examiner Signature	/Jennifer Kim/	Date Considered	07/22/2010
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 12

Confirmation Number

7706

Application Number

10/813,965

Filing Date

March 31, 2004

First Named Inventor

Robert Falotico

Group Art Unit

1628

Examiner Name

Jennifer M. Kim

Attorney Docket Number

CRD5073USNP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
	5,339,906	A		Fox, et al.	08-23-1994	
	5,350,800	A		Verhoeven, et al.	09-27-1994	
	5,350,866	A		Holton, et al.	09-27-1994	
	5,352,805	A		Nakata, et al.	10-12-1993	
	5,362,831	A		Mongelli, et al.	11-08-1994	
	5,380,751	A		Chen	01-10-1995	
	5,395,850	A		Roth	03-07-1995	
	5,400,056	A		Klein, et al.	08-08-1995	
	5,411,984			Kingston, et al.	05-02-1995	
	5,412,092			Rey, et al.	05-02-1995	
	5,415,938	A		Cabalan, et al.	05-16-1995	
	5,422,364			Nicolaou	06-06-1995	
	5,516,770	A		Waranis, et al.	05-14-1996	
	5,837,313	A		Ding, et al.	11-17-1998	
	5,891,845	A		Myers	04-06-1999	
	5,924,897			Campbell	07-20-1999	
	6,099,562	A		Ding, et al.	08-08-2000	
	6,120,536	A		Ding, et al.	09-19-2000	
	6,153,252	A		Hossainy, et al.	11-28-2000	
	6,241,762	B1		Shanley	06-05-2001	

Examiner Signature	/Jennifer Kim/	Date Considered	07/22/2010
--------------------	----------------	-----------------	------------

¹ Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 702.05. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kind Codes of U.S. Patent Documents at www.uspto.gov. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (06-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNPs

U.S. PATENT DOCUMENTS

Examiner Signature	Jennifer Kim/	Date Considered	07/22/2010
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional); 2See http://www.uspto.gov; 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3); 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6Applicant is to place a check mark here if English language is attached.</p>			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /JK/

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Approved for use through 12/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Confirmation Number 7706
Application Number 10/813,965
Filing Date March 31, 2004
First Named Inventor Robert Falotico
Group Art Unit 1628
Examiner Name Jennifer M. Kim
Attorney Docket Number CRD5073JUSNP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 12

FOREIGN PATENT DOCUMENTS

Examiner / Jennifer Kim/ Date 07/22/2010
Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See www.uspto.gov. ³Japanese patent documents: the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of English language by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (JK)





INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials * 	Cite No. † 	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published 	‡ 
		AJROLDI, G., et al. "Fluoroelastomers-Dependence of Relaxation Phenomena on Composition", Polymer (1969) Vol. 30, p. 2180-2187	
		ANDERSON, T., et al. "The Effect of Cholesterol-Lowering and Antioxidant Therapy on Endothelium-Dependent Coronary Vasomotion", The New England Journal of Medicine, Vol. 332, No. 8, pp. 488-493 (February 23, 1995)	
		BENEDECK, M., et al. "Smooth Muscle Cell Migration and Matrix Metalloproteinase Expression After Arterial Injury in the Rat", Circulation Research pp. 539-545 (1994)	
		BERK, B., et al. "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty", J. Am. Coll. Cardiol. Vol. 17 (Suppl B); pp. 111B-117B (1991)	
		BEUTLER, E., et al. "Cladribine (2-Chlorodeoxyadenosine)", The Lancet (1992) Vol. 340, pp. 952-956	
		BREHM, B., et al. "β-Blockers of the Third Generation Inhibit Endothelin-1-Liberation, mRNA Production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells", Journal of Cardiovascular Pharmacology", (2000) Suppl. 1, Vol. 36, pp. S401-S403	
		BREHM, B., et al. "Chronically Elevated Endothelin-1 Concentrations Modulate the β-Adrenergic Receptor System In Vitro and in Vivo", Journal of Cardiovascular Pharmacology (2000) Suppl. 1, Vol. 36, p. S157-S159	
		BURTON, G., et al. "β-Carotene: An Unusual Type of Lipid Antioxidant", Science, Vol. 224 (1984) pp. 569-573	
		CARRERA, C., et al. "Potent Toxicity of 2-Chlorodeoxyadenosine Toward Human Monocytes In Vitro and In Vivo", J. Clinical Investigation Vol. 86 pp. 1480-1488 (1990)	
		CARSON, D., et al. "Specific Toxicity of 2-Chlorodeoxyadenosine Toward Resting and Proliferating Human Lymphocytes", Book 62 pp. 737-743 (1983)	
		CHANG, M., et al. "Adenovirus-Mediated Over-Expression of the Cyclin/Cyclin-Dependent Kinase Inhibitor", J. Clinical Investigation, Vol. 96, pp. 2260-2268 (1995)	
		CLOWES, A., et al. "Kinetics of Cellular Proliferation After Arterial Injury, II. Inhibition", Lab. Invest. Vol. 52(6) pp. 611-616 (1985)	
		CLOWES, A., et al. "Kinetics of Cellular Proliferation After Arterial Injury, IV. Heparin", Circulation Research Vol. 58, p. 839-845 (1986)	
		CLOWES, A., et al. "Suppression of Heparin of Smooth Muscle Cell Proliferation in Injured Arteries", Nature Vol. 265 pp. 25-26 (1977)	

Examiner
Signature

/Jennifer Kim/

Date
Considered

07/22/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials * X	Cite No. * X	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published X	T ²
		COLBURN, M, et al. "Dose Responsive Suppression of Myointimal Hyperplasia by Dexamethasone", J. Vascular Surgery, Vol. 15 pp. 510-518 (1992)	
		CURRIER, J., et al. "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Target?" JACC, Vol. 25, No. 2, pp. 516-520 (1995)	
		CURRIER J., et al. "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit", Circulation 80, No. 4, pp. 11-66 (1989)	
		DEROANNE, C., et al. "Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular Endothelial Growth Factor Signaling", Oncogene (2002) Vol. 21, pp. 427-436	
		EDELMAN, E. et al. "Pathobiologic Responses to Stenting", American Journal of Cardiology, Vol. 81, Issue 7, Suppl. 1 (April 1998) pp. 4E-6E	
		FARB, A., et al. "Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2-Saporin Fusion Protein", Circulation Research Vol. 80(4) pp. 542-550 (1997)	
		FERNS, G., et al. "Inhibitors of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF", Reports p. 1129-1132 (1991)	
		FERNS, G., et al. "Probulcol Inhibits Neointimal Thickening and Macrophage Accumulation After Balloon Injury in the Cholesterol-Fed Rabbit", Proc. National Academy Science, Vol. 89, pp. 11312-11316 (1992)	
		FLEISCHMAN, L., et al. "Ras-Transformed Cells: Altered Levels of Phosphatidylinositol-4,5-Bisphosphate and Catabolite", Reports (1986) pp. 407-410	
		FRANKE, T. et al. "P13K Downstream AKTIIon Blocks Apoptosis", Cell. Vol. 88, pp. 435-437 (1997)	
		FUKUYAMA, J., et al. "Tranilast Suppresses Intimal Hyperplasia After Balloon Injury In Rabbits Fed On a high-Cholesterol Diet", European Journal of Pharmacology, Vol. 318 pp. 327-332 (1996)	
		GALIS, Z., et al. "Cytokine-Stimulated Human Vascular Smooth Muscle Cells Synthesize a Complement of Enzymes Required for Extracellular Matrix Digestion", Circulation Research Vol. 75 pp. 181-189 (1994)	
		GEORG, G., et al. "Synthesis of Biologically Active Taxol Analogues with Modified Phenylisoserine Side", J. Medical Chemistry, Vol. 35 pp. 4230-4237 (1992)	
		GIMON, M., et al. "Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry of Paclitaxel and Related Taxanes", Journal of Natural Products, Vol. 57(1) pp. 1404-1410 (1994)	
		GUIETTE-VOEGELEIN, F., et al. "Relationships Between The Structure of Taxol Analogues and Their Antimitotic Activity", J. Medical Chemistry, Vol. 34 pp.992-998 (1991)	

Examiner
Signature

/Jennifer Kim/

Date
Considered

07/22/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinda Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		GUYTON, J., et al. "Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin", Circulation Research, Vol. 46(5) pp. 625-634 (1980)
		HAAS-KOGAN, D., et al. "Protein Kinase B (PKB/akt) Activity is Elevated in Glioblastoma Cells Due to Mutation of the Tumor Suppressor PTEN/MMAC", Current Biology, Vol. 8(21) pp. 1195-1198 (1998)
		HANSSON, G., et al. "Interferon-Gamma Inhibits Arterial Stenosis After Injury", Circulation, 84 pp. 1266-1272 (1991)
		HANSON, S., et al. "Interruption of Acute Platelet-Dependent Thrombosis by the Synthetic Antithrombin D-Penylalanyl-propyl-arginyl chloromethyl Ketone", Proc. Nat. Academy of Science, Vol. 85 pp. 3184-3188 (1988)
		HOLTON, R., et al. "A Synthesis of Taxusin", J. American Chemical Society, Vol. 110 No. 19 pp. 6558-6560 (1988)
		IKADA, Y., et al. "Star-complex Formulation Between Enantiometric Poly(lacides)", Macromolecules 20 pp. 904-906 (1987)
		JONASSON, L., et al. "Cyclosporin A Inhibits Smooth Muscle Proliferation in the Vascular Response to Injury", Proc. Nat. Acad. Sci (USA) Vol. 85 (April 1988) pp. 2303-2306
		KU, G., "Inhibition by Probulcol of Interleukin 1 Secretion and Its implication in Atherosclerosis", American J. Cardiology Vol. 62 pp. 77B-81B (1988)
		KUGIYAMA, K., et al. "Impairment of Endothelium-Dependent Arterial Relaxation by Lyssolecithin in Modified Low-Density Lipoproteins", Nature, Vol. 344 pp. 160-162
		KUNISHIMA, T., et al. "A Randomized Trial of Aspirin Versus Cilostazol Therapy After Successful Coronary Stent Implantation", Clinical Therapeutics, Vol. 19(5) pp. 1058-1066 (1997)
		KUZUYA, M., et al. "Probulcol Prevents Oxidative Injury to Endothelial Cells", Journal of Lipid Research, Vol. 32 pp. 197-204 (1991)
		LANG, R., et al. "Effects of Okadaic Acid and ATPyS on Cell Length and Ca ²⁺ Channel Currents Recorded in Single Smooth Muscle Cells of the Guinea-pig Taenia Caeci", British J. pharmacol. (1991) pp. 331-336

Examiner Signature	/Jennifer Kim/	Date Considered	07/22/2010
-----------------------	----------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials * ↓	Cite No. * ↓	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ↓	T ↓
		LANGILLE, B., et al. "Reductions in Arterial Diameter Produced by Chronic Decreases in Blood Flow Are Endothelium-Dependent", <i>Reports, Science</i> , Vol. 231 pp. 405-407 (1986)	
		LEE, Y., et al. "Effectiveness of Probulcol in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty", <i>Japan Heart J.</i> pp. 327-332 (1996)	
		<i>Circulation</i> : LEE 84: 11-299 Abstracts From the 64th Scientific Sessions (1991)	
		LEIBEL, S. et al. "Radiation Therapy for Neoplasms of the Brain", <i>J. Neurosurgery</i> Vol. 66 pp. 1-22 (1987)	
		LIU, M., et al. "Rapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit", <i>Circulation</i> 81, No. 3 pp. 1089-1093 (1990)	
		LONG, B., et al. "Paclitaxel Inhibits Progression of Mitotic Cells to G Phase by Interference With Spindle Formation Without Affecting Another Microtubule Functions During Anaphase and Telophase", <i>Cancer Research</i> Vol. 54 pp. 4355-4361 (1994)	
		UNDERGAN, C., et al. "Peptide Inhibition of Myointimal Proliferation by Angiopeptin, A Somatostatin Analogue", <i>JACC</i> , Vol. 17(6) pp. 132B-6B (1991)	
		MAJESKY, M., et al. "Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery", <i>Circulation Research</i> , Vol. 61(2) p. 296-300 (1987)	
		MARX, S., et al. "Caramycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells", <i>Circulation Research</i> Vol. 76(3) pp. 412-417 (1995)	
		MINTZ, G., et al. "Limitations of Angiography in the Assessment of Plaque Distribution in Coronary Artery Disease", <i>Circulation</i> , Vol. 93 pp. 924-932 (1996)	
		MINTZ, G., et al. "Arterial Remodeling After Coronary Angioplasty: A Serial Intravascular Ultrasound Study", <i>Circulation</i> , Vol. 94(1) pp. 35-43 (1996)	
		MINTZ, G., et al. "Intravascular Ultrasound Predictors of Restenosis After Percutaneous Transcatheter Coronary Revascularization", <i>JACC</i> , Vol. 27(7) p. 1678 (1996)	

Examiner Signature	Jennifer Kim/	Date Considered	07/22/2010
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of U.S. Patent Documents at www.uspto.gov. *Enter Office of the Emperor of the document, by the two-letter code (WIPO Standard ST). *For Japanese patent documents, the indication of the year of the reign of the Emperor may precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. If possible: *Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 12

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials * X	Cite No. * X	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		MORENA, H., et al. "Comparison of the Effects of Regional Ischemia, Hypoxia, Hyperkalemia, and Acidosis on Intracellular and Extracellular Potentials and Metabolism in the Isolated Porcine Heart", <i>Circulation Research</i> , Vol. 46(5) pp. 634 (1980)
		NEMECEK, G., et al. "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo", <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 245(3) pp. 1167-1174
		NUNES, G. "Combination of Vitamins C and E Alters the Response to Coronary Balloon Injury in the Pig", <i>Arterioscler. Thromb and Vascular Biol.</i> Vol. 15(1) pp. 156-165 (1995)
		OKADA, T., et al. "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation After Endothelial Injury Without Systemic Anticoagulation", <i>Neurosurgery</i> (1989), Vol. 25(6), pp. 892-898
		ORGILL, D., et al. "Current Concepts and Approaches to Wound Healing", <i>Critical Care Medicine</i> , Vol. 15(9) pp. 859-908 (1988)
		OZAKI, H., et al. "Calcium-Independent Phosphorylation of Smooth Muscle Myosin Light Chain by Okadiac Acid Isolated From Black Sponge", <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 243(3) pp. 1167-1173 (1987)
		PARTHASARATHY, S., et al. "Probulocil Inhibits Oxidative Modification of Low Density Lipoprotein", <i>J. Clinical Investigation</i> , Vol. 77 pp. 641-644 (1986)
		PAZDUR, R., et al. "The Taxoids' Paclitaxel (Taxol) and Docetaxel (Taxotere)" <i>Cancer Treatment Reviews</i> , Vol. 19 pp. 351-366 (1993)
		POWELL, J. "Inhibitors of Angiogenesis-Converting Enzyme Prevents Myointimal Proliferation After Vascular Injury" <i>Science</i> , Vol. 245 (186-188 (1989)
		POZZATI, E., "The Growth of Cerebral Cavernous Angiomas", <i>Neurosurgery</i> , Vol. 25(10) pp. 92-97 (1989)
		PULCANI, J., et al. "Preparation of 7-Modified Docetaxel Analogs Using Electrochemistry", <i>Tetrahedron Letters</i> , Vol. 35(52) p. 9709-9712 (1994)
		RAJAGOPALAN, S., et al. "Reactive Oxygen Species Produced by Macrophage-Derived Foam Cells Regulate the Activity of Vascular Matrix Metalloproteinases in Vitro", <i>J. Clinical Investigation</i> , Vol. 98(11) pp. 2572-2579 (1996)
		REISER, K., et al. "Enzymatic and Nonenzymatic Cross-Linking of Collagen and Elastin", <i>The FASAB Journal</i> , Vol. 6 pp. 2439-2449 (1992)

Examiner Signature	/Jennifer Kim/	Date Considered	07/22/2010
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 12

Confirmation Number

7706

Application Number

10/813,965

Filing Date

March 31, 2004

First Named Inventor

Robert Falotico

Group Art Unit

1628

Examiner Name

Jennifer M. Kim

Attorney Docket Number

CRD5073USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials * ↓	Cite No. * ↓	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ↓
		RINGEL, I., et al. "Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol", J. National Cancer Institute, Vol. 83(4) pp. 288-291 (1991)
		SAITO, N., et al. "Intramedullary Cavernous Angioma With Trigeminal Neuralgia: A Case Report and Review of the Literature", Neurosurgery pp. 97-101 (1989)
		SCHIFF, P., et al. "Promotion of Microbutule Assembly in Vitro by Taxol", Nature, Vol. 277 p. 665-667 (1979)
		SCHNEIDER, J., et al. "Probucol Decreases Neointimal Formation in a Swine Model of Coronary Artery Balloon Injury", Circulation, Vol. 88 pp. 628-637 (1993)
		SCULLY, R., et al. "Case Records of the Massachusetts General Hospital", The New England Journal of Medicine p. 924 (1989)
		SERRUYS, P., et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Circulation Volume 93(3) pp. 412-422 (1996)
		SETSUDA, M., et al. "Probucol Therapy in the Prevention of Restenosis After Successful Percutaneous Transluminal Coronary Angioplasty", Clinical Therapeutics, Vol. 15(2) pp. 374-382 (1993)
		SHAYESTEH, L., et al. "PIK3CA is Implicated as an Oncogene in Ovarian Cancer", Nature Genetics, Vol. 21 pp. 99-102 (1999)
		SIDDQUI, M., et al. "Isolation and Sequencing of a cDNA Coding for the Human DF3 Breast Carcinoma-Associated Antigen", Proc. National Academy of Science, Vol. 85 pp. 2320-2323 (1989)
		SIMONS, M., et al. "Antisense c-myb Oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation In Vivo", Nature, Vol. 359 pp. 67-70 (1992)
		SNOW, A., et al. "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", American Journal of Pathology, Vol. 73(2) pp. 313-330 (1990)
		SOLLOTT, S., et al. "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty in the Rat", The Journal of Clinical Investigation, Vol. 95 pp. 1869-1876 (1995)

Examiner Signature	/Jennifer Kim/	Date Considered	07/22/2010
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/12

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam. Initials ↓	Cite No. ↓	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ↓	T ²
		SOUTHGATE, K., et al. "Involvement of Extracellular-Matrix-Degrading Metalloproteinases in Rabbit Aortic Smooth-Muscle Cell Proliferation" <i>Biochem. J.</i> Vol. 288 pp. 93-99 (1992)	
		SOUTHHORN, P., et al. "Free Radicals in Medicine: Chemical Nature and Biologic Reaction", <i>Mayo Clin. Proc.</i> Vol. 63 pp. 381-389 (1988)	
		STEINBERG, D. , "Studies on the Mechanism of Action of Probucool", <i>American J. Cardiology</i> , Vol. 57 pp. 16H-21H (1986)	
		STIERLE, A., et al. "Taxol and Taxane Production by <i>Taxomyces Andreanae</i> , An Endophytic Fungus of Pacific Yew", <i>Science</i> , Vol. 260 pp. 214-216 (1993)	
		STRAUSS, B., et al. "Extracellular Matrix Remodeling After Balloon Angioplasty Injury in a Rabbit Model of Restenosis" <i>Circulation Research</i> , Vol. 75 pp. 650-658 (1994)	
		TAKE, S., et al. "Effect of Cilostazol in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty", <i>American J. of Cardiology</i> , Vol. 79 pp. 1097-1099 (1997)	
		TANAKA, H., et al. , "Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury", <i>Circulation</i> , Vol. 88, pp. 1788-1803 (1993)	
		TSUCHIKANE, E., et al. "Impact of Cilostazol in Restenosis After Percutaneous Coronary Balloon Angioplasty", <i>Circulation</i> , pp. 21-26 (1999)	
		WANI, M., et al. "Plant Anti-Tumor Agents. VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from <i>Taxus Brevifolia</i> ", <i>J. Am. Chem. Soc.</i> (1971) Vol. 93 pp. 2325-2327	
		WATANABE, K., et al. "Preventive Effects of Probucool on Restenosis After Percutaneous Transluminal Coronary Angioplasty", <i>American Heart Journal</i> , Vol. 132 No. 1, Part I pp. 23-29 (1996)	
		WEINBERGER, J., et al. "Intracoronary Irradiation; Dose Response for the Prevention of Restenosis in Swine", <i>International J. Radiation Oncology Biol. Phys.</i> Vol. 36(4) pp. 767-775 (1996)	
		WILEY AND SONS , Chapter 2: "Modern Fluoropolymers - High Performance Polymers for Diverse Applications", pp. 71-90 (1997)	
		WOO, S., et al. "Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors", <i>J. Med. Chemistry</i> (2002) Vol. 45, pp. 2877-2885	
		ZHANG, S., et al. "A New 11(1)-Abeo-Taxane from <i>Taxus Yunnanensis</i> ", <i>Journal of Natural Products</i> , Vol. 57(11) pp. 1580-1583 (1994)	

Examiner Signature	/Jennifer Kim/	Date Considered	07/22/2010
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/